US Stock MarketDetailed Quotes

NRSN NeuroSense Therapeutics

Watchlist
  • 1.820
  • +0.090+5.20%
Close Mar 28 16:00 ET
  • 1.800
  • -0.020-1.10%
Post 17:12 ET
24.87MMarket Cap-1921P/E (TTM)

About NeuroSense Therapeutics Company

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company. The firm is focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. It is involved in the 2b/3 clinical trial using its product candidate, PrimeC in patients with ALS and also commencing research into other possible indications for the drug, including Alzheimer’s and Parkinson’s diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Company Profile

SymbolNRSN
Company NameNeuroSense Therapeutics
Listing Date12/09/2021
Issue Price5.99
Founded2017
CEOMr. Alon Ben-Noon
MarketNASDAQ
Employees14
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address11 HaMenofim Street,Building B
CityHerzliya
ProvinceTel Aviv
CountryIsrael
Zip Code46725
Phone972-9-799-6183

Company Executives

  • Name
  • Position
  • Salary
  • Alon Ben-Noon
  • Chief Executive Officer and Director
  • 1.57M
  • Or Eisenberg
  • Chief Financial Officer and Principal Accounting Officer
  • 1.33M
  • Dr. Ferenc Tracik
  • Chief Medical Officer
  • 1.18M
  • Mark W. Leuchtenberger
  • Chairman of the Board
  • 1.48M
  • Dr. Revital Mandil-Levin
  • Director
  • --
  • Cary J Claiborne
  • Independent Director
  • 104.00K
  • Christine A. Pellizzari
  • Independent Director
  • 104.00K
  • Caren Deardorf
  • Independent Director
  • 91.00K

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
%Chg